Page last updated: 2024-09-02

ecopipam and homovanillic acid

ecopipam has been researched along with homovanillic acid in 3 studies

Compound Research Comparison

Studies (ecopipam)	Trials (ecopipam)	Recent Studies (post-2010) (ecopipam)	Studies (homovanillic acid)	Trials (homovanillic acid)	Recent Studies (post-2010) (homovanillic acid)
147	18	34	6,127	312	438

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (33.33)	18.7374
1990's	1 (33.33)	18.2507
2000's	1 (33.33)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Strassburg, CP; Tukey, RH	1
Barnett, A; Berger, JG; Chipkin, RE; Coffin, VL; Iorio, LC; McQuade, RD	1
Emmi, A; Rajabi, H; Stewart, J	1

Reviews

1 review(s) available for ecopipam and homovanillic acid

Article	Year
Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annual review of pharmacology and toxicology, 2000, Volume: 40 Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic	2000

Other Studies

2 other study(ies) available for ecopipam and homovanillic acid

Article	Year
Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity. The Journal of pharmacology and experimental therapeutics, 1988, Volume: 247, Issue:3 Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Benzazepines; Catalepsy; Dogs; Dopamine; Dopamine Antagonists; Homovanillic Acid; Male; Mice; Prolactin; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Stereotyped Behavior; Vomiting	1988
Behavioral and neurochemical recovery from partial 6-hydroxydopamine lesions of the substantia nigra is blocked by daily treatment with D1/D5, but not D2, dopamine receptor antagonists. The Journal of neuroscience : the official journal of the Society for Neuroscience, 1997, May-15, Volume: 17, Issue:10 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Benzazepines; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Homovanillic Acid; Male; Microdialysis; Oxidopamine; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D5; Substantia Nigra; Sympatholytics	1997

Article

Year

Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.

The Journal of pharmacology and experimental therapeutics, 1988, Volume: 247, Issue:3

Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Benzazepines; Catalepsy; Dogs; Dopamine; Dopamine Antagonists; Homovanillic Acid; Male; Mice; Prolactin; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Stereotyped Behavior; Vomiting

1988

Behavioral and neurochemical recovery from partial 6-hydroxydopamine lesions of the substantia nigra is blocked by daily treatment with D1/D5, but not D2, dopamine receptor antagonists.

The Journal of neuroscience : the official journal of the Society for Neuroscience, 1997, May-15, Volume: 17, Issue:10

Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Benzazepines; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Homovanillic Acid; Male; Microdialysis; Oxidopamine; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D5; Substantia Nigra; Sympatholytics

1997